Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IUB PRIMA is an intrauterine drug-delivery system developed as a targeted, controlled-release platform for the local treatment of uterine disorders. It utilizes OCON Therapeutics' proprietary IntraUterine Ball (IUB) 3D frame technology, which is designed to fit the uterine cavity and minimize risks such as malposition and perforation. The device delivers low-dose therapies directly to the uterus, aiming to reduce systemic side effects associated with oral or parenteral drugs. Its initial application is for long-term reversible contraception and management of heavy menstrual bleeding by locally releasing levonorgestrel into the uterine cavity. The platform also serves as a proof-of-concept for future targeted treatments of endometriosis and myomas/uterine fibroids using other drugs[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IUB PRIMA.